Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02448589 · ClinicalTrials.gov registry record · Phase 1
An Investigation of TAS-119 Monotherapy
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02448589 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 74 participants.
The verdict
NCT02448589, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
Interventions
- DRUG TAS-119
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02448589
The ClinicalTrials.gov registry entry for NCT02448589 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-119 is the first listed.
NCT02448589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02448589 about?
NCT02448589 is a clinical study titled "An Investigation of TAS-119 Monotherapy". A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients with Advanced Solid Tumors.
What is the current status of trial NCT02448589?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2014-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02448589?
The interventions under investigation include: TAS-119 (DRUG).
Who is sponsoring clinical trial NCT02448589?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.